Results 61 to 70 of about 903,302 (304)

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

New England Journal of Medicine, 2006
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic ...
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. L. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson   +31 more
semanticscholar   +1 more source

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital

Frontiers in Oncology, 2023
IntroductionAcute promyelocytic leukemia (APL) is a rare myeloid leukemia subtype affecting adult and pediatric populations. APL constitutes 15-20% of all childhood AML in Latin America, compared to 7% in the non-Latino population.
Marco Antonio Murillo-Maldonado, Paulina González Galván, Israel Parra Ortega, Félix Gaytán Morales, Félix Gaytán Morales, Luis Juárez Villegas, Elisa Dorantes Acosta, Elisa Dorantes Acosta   +7 more
doaj   +1 more source

Survival and predictors of mortality among acute leukemia patients on follow‐up in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A 5‐year retrospective cohort study

Cancer Reports, 2023
Background Although Ethiopia has more than 78% of leukemia cases and a significant burden of the disease, the survival of leukemia patients in the country is poorly recognized.
Bargude Balta, Tigistu Gebreyohannis, Erdaw Tachbele   +2 more
doaj   +1 more source

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

Haematologica, 2023
Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced ...
Patrick Harrington, Richard Dillon, Deepti Radia, Philippe Rousselot, Donal P. McLornan, Mark Ong, Anna Green, Alessandro Verde, Farzana Hussain, Kavita Raj, Shahram Kordasti, Claire Harrison, Hugues de Lavallade   +12 more
doaj   +1 more source

The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]

, 2017
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core   +1 more source

Leveraging current insights on IL‐10‐producing dendritic cells for developing effective immunotherapeutic approaches

FEBS Letters, EarlyView.
In vivo IL‐10 produced by tissue‐resident tolDC is involved in maintaining/inducing tolerance. Depending on the agent used for ex vivo tolDC generation, cells acquire common features but prime T cells towards anergy, FOXP3+ Tregs, or Tr1 cells according to the levels of IL‐10 produced. Ex vivo‐induced tolDC were administered to patients to re‐establish/
Konstantina Morali, Gloria Giacomello, Michela Vuono, Silvia Gregori   +3 more
wiley   +1 more source

Neutrophils in cancer: neutral no more [PDF]

, 2016
Neutrophils are indispensable antagonists of microbial infection and facilitators of wound healing. In the cancer setting, a newfound appreciation for neutrophils has come into view.
A Blaisdell, A Carus, A Görgens, A Hasenberg, A Kohler, A Mantovani, A Sparmann, A Stoppacciaro, A Swierczak, A Warnatsch, AD Friedman, AD Panopoulos, AJ Casbon, AJ Gentles, AJ Templeton, AK Mankan, AM Houghton, AM Wengner, AP Tittel, AS Chung, B Ruffell, BK Popivanova, BT Suratt, BZ Qian, C Cheretakis, C Gordy, C Martin, CF Wu, CH Ries, CL Semerad, CL Semerad, D Di Mitri, D Marvel, D Metcalf, D Zhang, DI Gabrilovich, DJ Cua, DR Welch, E Elinav, EB Eruslanov, EI Deryugina, EM Bekes, F Chen, F Colotta, F Kuonen, F Liu, F Liu, F Rosenbauer, F Shojaei, F Shojaei, F Shojaei, F Shojaei, G Molineux, G Wang, GJ Guthrie, GJ Lieschke, GO Ahn, H Hirai, H Ji, H Katoh, H Nozawa, H Takahashi, H Tazawa, HH Yan, HK Jensen, HK Kim, HL Rao, HS Deshmukh, I Mishalian, I Petit, J Adolfsson, J Cools-Lartigue, J Crawford, J Jablonska, J Jiao, J Mei, J Pillay, J Pillay, J Pillay, J Sceneay, JC Pahler, JD Spicer, JD Waight, JD Waight, JF Seymour, JI Youn, JI Youn, JL Granick, JL Guerriero, JM Daley, JM Petty, JP Levesque, JT Dancey, JT Erler, JY Sagiv, K Fiedler, K Kersten, K Kim, K Shang, K Shitara, K Tomihara, KA Charles, Karin E. de Visser, KE De Visser, KH Steinbach, KJ Eash, KJ Eash, L Benevides, L Deng, L Gong, L Strauss, L Yang, L Yang, LA Pekarek, LB Rivera, LJ Bayne, LM Coussens, LP Seung, M Bodogai, M Bruchard, M Di Maio, M Elkabets, M Hager, M Ishikawa, M Kowanetz, M Papaspyridonos, M Santoni, M Van Egmond, M Wislez, MA Lopez-Lago, MA Postow, MA Stark, Max D. Wellenstein, MF Denny, MG Manz, MH Kim, MK Richards, MK Srivastava, MP Keane, MT O'Toole, N Antonio, N Borregaard, N Borregaard, P Andreu, P Ehrlich, P Schwarzenberger, P Wu, PC Burdon, PC Vincent, PJ Murray, Q Ma, R Bertini, R Catena, R Noy, RA Caruso, RA Droeser, RN Kaplan, S Acharyya, S Basu, S Dogan, S Hiratsuka, S Tazzyman, S Tazzyman, S Tu, SB Coffelt, SB Coffelt, SB Forlow, Seth B. Coffelt, SH Chang, SH Saverymuttu, SI Rennard, SJ Huh, SJ Moghaddam, SK Bunt, SK Wculek, SL Gaffen, SL Highfill, T Bald, T El Rayes, T Jamieson, T Kitamura, T Lämmermann, T Tak, T Voloshin, T Yamanaka, TE Sutherland, TO Jensen, V Cortez-Retamozo, V Finisguerra, VT Phan, WJ McKinstry, X Qu, X Song, XD Yang, Y Carmi, Y Han, Y Ma, Y Pang, Y Pylayeva-Gupta, Y Sawanobori, Y Tsuda, Y Ueda, Y Ueda, Z Granot, Z Li, ZG Fridlender   +205 more
core   +1 more source

Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice

Molecular Therapy: Methods & Clinical Development, 2017
New methods to produce large numbers of myeloid progenitor cells, precursors to macrophages (MΦs), by maintaining Hoxb8 transcription factor activity1 has reinvigorated interest in MΦ cell therapies. We generated Hoxb8-dependent myeloid progenitors (HDPs)
Simon Lee, Saul Kivimäe, Francis C. Szoka   +2 more
doaj   +1 more source

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

New England Journal of Medicine, 2003
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.
S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker   +24 more
semanticscholar   +1 more source

FoxO1 signaling in B cell malignancies and its therapeutic targeting

FEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz   +3 more
wiley   +1 more source